An Interview with Cannulight

Introducing Cannulight to RedCrow’s Discover Platform! We sat down with James Stone, the inventor, founder, and CEO of Cannulight, to learn more about the company and its mission.

In a few sentences, describe your company, product, and innovation.
Cannulight is a small, sterile, single use, disposable medical device that aids peripheral intra venous cannulation/catheterization (PIVC). Cannulight gives an unambiguous binary signal (i.e. a green LED lights up) when the PIVC needle is in the vein. When the needle of the PIVC enters the vein the Cannulight LEd lights up green, indicating that it is in the correct position. If the needle exits the vein, the Cannulight turns off. The clinician can then reposition the needle

What is a recent milestone the company has achieved?
Cannulight Technology’s FDA pre-submission documentation for 510(k) clearance was accepted for review by the FDA on May 20th.

Is there a team member or advisor you’d like to spotlight?
We are a small team at present but have engaged the expertise we’ve needed to rapidly progress. This is mainly due to our COO Mike Munley’s global medtech experience couple with his international network. This includes RedCrow as Mike met the founders some time back at a US conference. Through Mike’s connections in Washington DC Cannulight Technology was invited to pitch to the US Marine Corps early in the products development. Resulting in the USMC applying for funding recently to test the device for US Military use.

Was there an “ah-ha” or personal moment that led to the founding of the company?
As a dentist specializing in treating anxious patients under IV sedation, a failure to catheterize meant procedures were canceled and patients sent home, agitated, and unlikely to return. After searching in vain for a solution, I resolved to try to develop one myself, resulting ultimately in my invention of Cannulight and the founding of Cannulight Technology.

RedCrow’s mission is to challenge the status quo in the name of better healthcare results. How does your mission reflect this?
Cannulight Technology’s vision is for Cannulight devices to become the indispensable aids to every peripheral intra venous cannulation/catheterization (PIVC), and to improve patient and clinician outcomes and experiences in all situations. PIVC is the most performed invasive procedure in the world at over 1billion pa. However a failure rate of 35-70% means many patients, especially children, the elderly and the obese suffer injury and stress as a result. We believe Cannulight will improve outcomes for these patients and the clinicians who treat them.

How is your company keeping up with or participating in the changing landscape of healthcare?
Cannulight Technology is a simple device that can be safely disposed of in medical sharps waste. By reducing PIVC failures, sharps waste will likely decrease overall. The device can also enables less experienced clinicians to perform PIVC with confidence, so it is likely to be adopted for in-home treatments, empowering patients and caregivers.

Disclaimer: The opinions expressed in this blog are those of the authors and do not represent the views and opinions of RedCrow or its affiliates. The blog does not imply a recommendation or endorsement by Redcrow. RedCrow does not verify or establish the truth of the information obtained in the blog. These materials may not be relied upon for making any investment decision. Nothing in the blog is to be construed as a securities offering.

Leave a Reply

Your email address will not be published. Required fields are marked *

Site Disclaimer

Want to learn more about investing in Regulation Crowdfunding (Reg CF)? Access our investor educational material here.

Important Disclosures

The www.RedCrow.com website (the “Website” or “Site”) is operated by Red Crow Crowd Inc. (“RedCrow”) and owned by Alira Health Transaction Services. Sections of this website are used by Alira Health Transaction Services (FINRA CRD No. 140203), which is a registered broker-dealer and a member of FINRA | SIPC. Information on all FINRA registered broker-dealers can be found on FINRA’s BrokerCheck. All securities-related activity is conducted by Alira Health Transaction Services, located at 1 Grant St, Framingham, Massachusetts 01702. Neither RedCrow or Alira Health Transaction Services provides investment advice or makes investment recommendations on this website; nothing posted on the Site should be construed as such. No communication, through this website or in any other sections of this website or medium should be construed as a recommendation for any security offered on or off this investment platform.

Alternative investments are speculative, involve a high degree of risk and are not suitable for all investors and you should not invest unless you are able to sustain the risk of loss of your entire investment. Complete loss of principal is possible. Private placements are unregistered securities, considered illiquid and long-term investments. Distributions are not guaranteed. Investing in securities involves risks, and there is always the potential of losing money when you invest in securities.

Content provided is for informational purposes only and is not intended to be an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities or a solicitation of any such offer. Information provided does not take into account an investor’s specific objectives or risk profile. Investment decisions should be made based on your objectives and circumstances and in consultation with your own advisors. Alira Health Transaction Services does not provide tax, legal or accounting advice. Please consult with and rely on a qualified professional.

By accessing this website and any pages thereof, you agree to be bound by the Terms of Use.

Form CRS | Regulation Best Interest | Business Continuity Plan | Privacy Policy | Electronic Delivery Consent.